The acute respiratory distress syndrome (ARDS) is a life-threatening condition that causes
respiratory failure. Despite numerous clinical trials, there are no molecularly targeted …

After dozens of clinical trials, there are still no Food and Drug Administration–approved
drugs that improve mortality in acute respiratory distress syndrome (ARDS). These poor …

Abstract Acute Respiratory Distress Syndrome (ARDS), associated with Covid-19 infections,
is characterized by diffuse lung damage, inflammation and alveolar collapse that impairs …

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are serious lung
injuries caused by various factors, leading to increased permeability of the alveolar-capillary …

Introduction: Respiratory infections and diseases are accompanied by or exhibit
inflammation. Recent advances in nanoparticle engineering technology, together with the …

Acute lung injury and acute respiratory distress syndrome (ARDS) represent a heterogenous
group of lung disease in critically ill patients that continues to have high mortality. Despite …

Pulmonary diseases pose an immense threat to global health. Several nanotherapeutics-
based approaches aimed to tackle pulmonary ailments in recent years. The current …

In 2007, Bosma et. al provided a comprehensive review of emerging therapies for the acute
respiratory distress syndrome (ARDS), a condition which continues to carry a mortality rate …

Inhaled drug delivery has been an emerging route for the treatment of lung diseases with
clear advantages over oral and intravenous routes. However, the delivery efficacy is affected …

Acute respiratory distress syndrome (ARDS) is a form of oxygenation failure primarily
characterized by rapid inflammation resulting from a direct pulmonary or indirect systemic …